J. Green

发表

Association of lactose sensitivity with inflammatory bowel disease – demonstrated by analysis of genetic polymorphism, breath gases and symptoms

A. Campbell, J. Waud, S. Matthews, 2011, Alimentary pharmacology & therapeutics.

Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis

R. Newcombe, C. Feyerabend, W. Sandborn, 1997, Clinical pharmacology and therapeutics.

Nicotine enemas for active ulcerative colitis—a pilot study

C. Feyerabend, W. Sandborn, M. Russell, 1997, Alimentary pharmacology & therapeutics.

Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis

G. Williams, J. Green, G. Williams, 2000, Alimentary pharmacology & therapeutics.

An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics.

C. Feyerabend, M. Russell, J. Green, 1999, British journal of clinical pharmacology.

Clinical status of ulcerative colitis in patients who smoke

C. Feyerabend, G. Williams, V. Mani, 1998, American Journal of Gastroenterology.

Inflammatory bowel disease and smoking : A review

J. Green, G. Thomas, J. Rhodes, 1998 .

Nicotine tartrate liquid enemas for mildly to moderately active left‐sided ulcerative colitis unresponsive to first‐line therapy: a pilot study

K. Batts, R. Hurt, K. Offord, 1997, Alimentary pharmacology & therapeutics.

A dose‐ranging pharmacokinetic study of nicotine tartrate following single‐dose delayed‐release oral and intravenous administration

A. Zinsmeister, R. Hurt, K. Offord, 1997, Alimentary pharmacology & therapeutics.

Nicotine: therapeutic potential for the treatment of ulcerative colitis.

J. Green, J. Rhodes, G. Thomas, 1997, Expert opinion on investigational drugs.

Controlled trial of antituberculous chemotherapy in Crohn’s disease: a five year follow up study

R. Newcombe, G. Strohmeyer, J. Green, 1998 .

Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study.

R. Newcombe, G. Strohmeyer, J. Green, 1998, Gut.

Enteric‐release glyceryl trinitrate in active Crohn’s disease: a randomized, double‐blind, placebo‐controlled trial

J. Mayberry, J. Green, J. Kingham, 2001, Alimentary pharmacology & therapeutics.

Megacystis-microcolon-intestinal hypoperistalsis syndrome and the absence of the α3 nicotinic acetylcholine receptor subunit

Geraint T. Williams, G. Thomas, B. Jasani, 2001 .

Bacterial metabolic 'toxins': a new mechanism for lactose and food intolerance, and irritable bowel syndrome.

A. Campbell, I. Holland, C. D. Cox, 2010, Toxicology.

Quantifying the ‘hidden’ lactose in drugs used for the treatment of gastrointestinal conditions

A. Campbell, J. Waud, S. Matthews, 2009, Alimentary pharmacology & therapeutics.

Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel.

J. Green, B. Evans, H. Mckirdy, 1999, European journal of gastroenterology & hepatology.

Differential effect of nitric oxide synthase inhibition on sigmoid colon longitudinal and circular muscle responses to nicotine and nerve stimulation in vitro

J. Green, R. Marshall, H. Mckirdy, 2004, The British journal of surgery.

Nicotine carbomer enemas--pharmacokinetics of a revised formulation.

C. Feyerabend, W. Sandborn, M. Russell, 1998, Italian journal of gastroenterology and hepatology.

Effect of smoking and transdermal nicotine on colonic nicotinic acetylcholine receptors in ulcerative colitis.

B. Jasani, G. Williams, J. Lindstrom, 2003, QJM : monthly journal of the Association of Physicians.

Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub‐clinical inflammation and the impact on clinical assessment of disease activity

A. Campbell, K. Hood, J. Green, 2013, Alimentary pharmacology & therapeutics.